Phenotypes and treatment strategies for pulmonary hypertension in interstitial lung disease

A PH Group III webinar

The Pulmonary Hypertension Group III Workstream was founded in March 2021 and serves as a collaborative platform between industry, academic, regulatory, and patient representatives. Its aim is to strengthen our community’s understanding of pulmonary hypertension due to lung diseases.

Presentations 

• Is there evidence for different phenotypes of PH in ILD? Lucilla Piccari, Hospital del Mar, Spain, Oksana Shlobin, Inova Hospital, USA
• Treatment of pulmonary vascular disease in ILD: as early as possible or only in severe PH? John Wort, Royal Brompton Hospital, UK, Steven Nathan, Inova Hospital, USA

Moderated by Steven Nathan, Inova Hospital, USA, and Sylvia Nikkho, Bayer, Germany